Regeneron’s ROXI-PALISADE Trial Targets Safer Clot Prevention in Peripheral Artery Disease

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.

The ROXI-PALISADE Phase 3 trial, formally titled “A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933…,” tests new blood clot prevention drugs in adults with peripheral artery disease after leg vessel procedures. The study focuses on cutting serious clot events in a high-risk group, a large unmet need in cardiovascular care.

The trial evaluates two injectable antibodies, REGN7508 (cenvacibart) and REGN9933 (amrecibart), which block Factor XI, a clotting protein. They aim to reduce dangerous clots while avoiding the bleeding risks often seen with older blood thinners like rivaroxaban.

This is a randomized, Phase 3 treatment study with parallel groups, meaning patients are split into distinct arms that run at the same time. Most participants and study staff are blinded to which study drug or placebo is given, though rivaroxaban in one cohort is given open-label to allow real-world comparison.

The study started after its first submission on January 2, 2026, marking the official launch of the trial program. The latest update on May 19, 2026, shows the status as recruiting, signaling steady operational progress but still years to go before full readout.

For investors, this update reinforces Regeneron’s push into cardiovascular risk beyond its core eye and inflammatory franchises, adding a new potential revenue pillar. Success could pressure incumbents in clot prevention, including makers of rivaroxaban and other anticoagulants, and support a higher long-term growth multiple for REGN.

The ongoing ROXI-PALISADE study remains in active recruitment, and further details and updates are available on the ClinicalTrials.gov portal.

To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.